Erythromycin NDC 51407-853

NDC codes

FDA NDC Directory

Product NDC (as listed)51407-853Labeler and product segments. Claims need a package NDC.

Product NDC at billing width51407-0853Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
51407-853-30	51407085330	30 TABLET, DELAYED RELEASE in 1 BOTTLE (51407-853-30)Marketed from Dec 7, 2023

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Erythromycin
Generic name (nonproprietary): erythromycin
Active ingredients: Erythromycin — 250 mg/1
Dosage form: Tablet, Delayed release
Route: Oral
Labeler: Golden State Medical Supply, Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 211975
Marketing start: Jul 26, 2021
Listing expires: Dec 31, 2026
Other FDA classes: Decreased Sebaceous Gland Activity (Physiologic effect)Macrolides (Chemical structure)
Identifiers: Product ID 51407-853_27c1ce89-9cfb-b5af-e063-6394a90a151bSPL ID 27c1ce89-9cfb-b5af-e063-6394a90a151bSPL set ID 0c0560be-fb11-509d-e063-6394a90ab6f7RxCUI 310155, 310157UNII 63937KV33D
Pharmacologic class: Macrolide Antimicrobial; Macrolide

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N451407085330 followed by a unit qualifier and the quantity

Package 51407-0853-30. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Nov 25, 2024.

Indications (excerpt from the label)

INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin delayed-release tablets and other antibacterial drugs, erythromycin delayed-release tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Erythromycin delayed-release tablets are indicated in the treatment of infections caused by susce…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 211975

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 211975
Product	Strength	Form · route	Labeler	Product NDC
Erythromycin	Erythromycin 333 mg/1	Tablet, Delayed releaseOral	Torrent Pharmaceuticals Limited	13668-587
Erythromycin	Erythromycin 250 mg/1	Tablet, Delayed releaseOral	Torrent Pharmaceuticals Limited	13668-586
Erythromycin	Erythromycin 500 mg/1	Tablet, Delayed releaseOral	Torrent Pharmaceuticals Limited	13668-588
Erythromycin	Erythromycin 500 mg/1	Tablet, Delayed releaseOral	Golden State Medical Supply, Inc.	51407-854